Back to Watchlist

Evidence memo

NAD+ / NR / NMN

Also tracked as: Nicotinamide riboside, Nicotinamide mononucleotide, NAD boosters

Human studies show NAD-biomarker movement, while durable clinical-outcome claims remain much less certain.

Randomized human data

Evidence status

Peptide and compound claims to watch. Evidence level: Randomized human data.

Claim being evaluated

Whether raising NAD-related biomarkers improves clinically meaningful outcomes rather than only changing lab measures.

Why people care

NAD biology is central to aging narratives, mitochondrial function, and supplement marketing.

Signal so far

Randomized human studies support biomarker movement and selected functional signals, but longevity or disease-prevention conclusions are not established.

Biggest unknown

Which populations benefit, which endpoints matter, long-term safety, and whether biomarker changes translate into outcomes.

Safety/regulatory boundary

Biomarker movement is not the same as a clinical outcome.

Watch next

Longer trials, clinical endpoints, tissue-specific data, and independent replication.

Evidence interpretation

Better human evidence than many longevity compounds, but still often oversold.

References